LSD moderately increased blood pressure and heart rate. The average duration of subjective effects increased from 6.7 to 11 h with increasing doses of 25–200 µg. The 200 µg dose of LSD induced greater ego dissolution than the 100 µg dose and induced significant anxiety.
A ceiling effect was observed for good drug effects at 100 µg. LSD showed dose-proportional pharmacokinetics and first-order elimination and dose-dependently induced subjective responses starting at the 25 µg dose. The pharmacokinetic-subjective response relationship was evaluated. Outcome measures included self-rating scales that evaluated subjective effects, autonomic effects, adverse effects, plasma brain-derived neurotrophic factor levels, and pharmacokinetics up to 24 h.
Test days were separated by at least 10 days. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25 h sessions and received placebo, LSD (25, 50, 100, and 200 µg), and 200 µg LSD 1 h after administration of the serotonin 5-hydroxytryptamine-2A (5-HT 2A) receptor antagonist ketanserin (40 mg). However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy.
0 kommentar(er)
